Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Rohlff

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Expert Review of Proteomics|June 22, 2005
New approaches towards integrated proteomic databases and depositoriesChristian Rohlff
Biological Psychiatry|May 14, 2003
Modern proteomic strategies in the study of complex neuropsychiatric disordersChristian Rohlff, Kate Hollis
Current Opinion in Molecular Therapeutics|July 26, 2002
Proteomic approaches to central nervous system disordersChristian Rohlff, Christopher Southan
Oncotarget|April 19, 2017
Targeting CD157 in AML using a novel, Fc-engineered antibody constructChristina Krupka, Felix S Lichtenegger, Thomas Köhnke, et al.
Molecular Cancer Therapeutics|June 23, 2019
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid TumorsGiuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Expert Review of Proteomics|June 22, 2005
New approaches towards integrated proteomic databases and depositoriesChristian Rohlff
Biological Psychiatry|May 14, 2003
Modern proteomic strategies in the study of complex neuropsychiatric disordersChristian Rohlff, Kate Hollis
Current Opinion in Molecular Therapeutics|July 26, 2002
Proteomic approaches to central nervous system disordersChristian Rohlff, Christopher Southan
Oncotarget|April 19, 2017
Targeting CD157 in AML using a novel, Fc-engineered antibody constructChristina Krupka, Felix S Lichtenegger, Thomas Köhnke, et al.
Molecular Cancer Therapeutics|June 23, 2019
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid TumorsGiuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Pageof 1